Clinical trials: Pulmonary Hypertension
Hypertension, Pulmonary
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension.
- Trial name
- NCT01824290
- Testing
- Tadalafil, ERA as specific PAH treatment
- Where
- 43 sites in United States, Austria and 12 more
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Pulmonary Hypertension
Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension
OBJECTIVES: I. Determine the safety and efficacy of UT-15 in patients with severe symptomatic primary pulmonary hypertension.
- Trial name
- NCT00004497
- Testing
- UT-15
- Where
- 7 sites in United States
- Sponsor
- United Therapeutics
1- Haemodynamic Phenotyping of the Out - of - Proportion PH to Guide Different Therapeutic Lines
Phenotyping of the Out-of-proportion Pulmonary Hypertension
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases.
- Trial name
- NCT06051396
- Testing
- Right sided heart catheterization
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Pulmonary Arterial Hypertension
Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults
This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.
- Trial name
- NCT05938946
- Testing
- L608 Inhalation Solution
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Pulmonary Hypertension (PH), End Stage Kidney Disease (ESRD)
Euvolemia-Based Assessment of Pulmonary Hypertension in Stable Hemodialysis Patients
Pulmonary hypertension (PH) is a frequent and clinically significant complication in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis (HD).
- Conditions
- Pulmonary Hypertension (PH), End Stage Kidney Disease (ESRD), Hemodialysis Patients, Volume Overload
- Trial name
- EU-PHASE-HD (NCT07676786)
- Testing
- Observational Assessment
- Where
- 2 sites in Romania
- Volunteers
- 30 people
- Sponsor
- Stefan Lujinschi
Cardiovascular Diseases
Identification of Genetic Markers for Cardiopulmonary Diseases (Genotype)
This study is designed to investigate whether an association exists between certain genes/protein levels and the development of various cardiopulmonary diseases.
- Trial name
- Genotype (NCT00616369)
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- University of Alabama at Birmingham
Erythrocytosis, Pulmonary Hypertension
Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis
Some people develop erythrocytosis, a condition characterized by having too many red blood cells, because of inherited changes (mutations) in genes such as EPAS1, EGLN1, or VHL.
- Conditions
- Erythrocytosis, Pulmonary Hypertension, Thrombosis
- Trial name
- NCT07895966
- Testing
- Belzutifan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Utah
Allergic Rhinitis, Asthma
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
The specific aim of this proposed project is to implement a standard process for integrating MedlinePlus health information prescriptions into the clinic workflow.
- Conditions
- Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy
- Trial name
- NCT00634608
- Testing
- Health Information Prescription
- Where
- United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Pregnancy Related, Fetal; Circulation
Doppler Ultrasonographic Assessment of Fetal Internal Thoracic Artery Indexes
The aim of this study is to assess the feasibility of visualizing the internal thoracic artery (ITA), establishing the normogram for ITA pulsatility index (PI), resistance index (RI) and acceleration/ejection time (AT/ET) at…
- Trial name
- NCT04686240
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Ankara City Hospital Bilkent
Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Knowledge Translation Program for the guidelines and evidence-based management of PAH patients
- Trial name
- PAH QuERI Ext (NCT01389206)
- Testing
- observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 797 people
- Sponsor
- Actelion
Heart Failure, Diastolic, Pulmonary Hypertension
Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH
Aim of the study is to investigate whether Sildenafil treatment results in a reduction of pulmonary artery pressure without decrease of cardiac output (CO) and in improvement of exercise capacity in patients with heart failure…
- Trial name
- NCT01726049
- Testing
- Sildenafil
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- University Medical Center Groningen
Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy
A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST
This project aims to conduct a prospective, multicenter, randomized controlled clinical trial. The study plans to enroll 270 patients with locally advanced iCCA who have successfully undergone GOLP conversion therapy.
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy, TDTP-RECIST, GOLP Regimen
- Trial name
- NCT07208526
- Testing
- GOLP regimen, Surgery, TDTP-RECIST
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Shanghai Zhongshan Hospital
Pulmonary Arterial Hypertension
Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension
Pulmonary hypertension is a rare condition that leads to right ventricular dysfunction and premature death. Only modest improvements of outcomes have been observed with the current available advanced specific drug therapy.
- Trial name
- DENERV'AP (NCT02525926)
- Testing
- denervation
- Where
- 5 sites in France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Pulmonary Arterial Hypertension
Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan
This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.
- Trial name
- NCT01251835
- Testing
- Sitaxsentan alone, Sitaxsentan, Rifampin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Hypertension
Remote Exercise Program Delivery Using a Mobile Application for Pulmonary Arterial Hypertension
This study will determine the feasibility of a mobile application-based home exercise rehabilitation program for patients with pulmonary hypertension.
- Trial name
- REVAMP (NCT04559516)
- Testing
- Exercise Intervention, Standard Care
- Where
- Canada
- Sponsor
- University of Calgary
Multidetector Computed Tomography, Pulmonary Embolism and Thrombosis
Lung Perfusion Measured With Dual-Energy CT in Patients With Chronic Thromboembolic Pulmonary Hypertension: Comparative Study With Right Heart Catheterization and V/Q
A comparative, observational, cross-sectional and prolective diagnostic test study, including patients that have had a right heart catheterization and were referred for a CT pulmonary angiography as part of their imaging workup…
- Conditions
- Multidetector Computed Tomography, Pulmonary Embolism and Thrombosis, Hypertension Pulmonary Secondary
- Trial name
- NCT03450304
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Pulmonary Arterial Hypertension
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07143448
- Testing
- HS235
- Where
- 4 sites in United States, Spain and 1 more
- Volunteers
- 90 people
- Sponsor
- 35Pharma Inc., a GSK company
Pulmonary Arterial Hypertension
A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor
A multinational, multicenter, double-blind, randomized, placebo-controlled, Phase III study to assess the efficacy and safety of BPS 314d-MR in subjects with pulmonary arterial hypertension currently receiving treatment with an…
- Trial name
- NCT01458236
- Testing
- Beraprost Sodium 314d Modified Release Tablets
- Sponsor
- Lung Biotechnology PBC
Pulmonary Hypertension, End-Stage Renal Disease
Impact of Hemo-dialysis Therapy on Blood Levels of Treprostenil in End Stage Renal Disease Patients With Pulmonary Hypertension
Remodulin (Treprostenil sodium) is synthetic prostacyclin analog available as a solution for administration in the intravenous route.
- Conditions
- Pulmonary Hypertension, End-Stage Renal Disease, Hemo-dialysis Therapy
- Trial name
- NCT01234571
- Volunteers
- 5 people
- Sponsor
- Rambam Health Care Campus
Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)
International Registry of Congenital Portosystemic Shunt (IRCPSS)
Congenital Portosystemic Shunt (CPSS) is a rare condition important by the multiplicity and severity of associated complications.
- Trial name
- IRCPSS (NCT06041906)
- Testing
- Shunt Closure
- Where
- 26 sites in United States, Australia and 14 more
- Volunteers
- 500 people
- Sponsor
- Prof. Valérie Mc Lin